As a contrast, the researchers compared the treatment of different cells using PFCDs: lung cancer cell A549 (which doesn’t express PSMA), normal prostate cell RPWE-1 (with low PSMA expression), and PSMA+ LNCaP PCa cell. This evidence concerns the gene FOLH1 and lung carcinoma.